Cargando…

Taurine: a potential marker of apoptosis in gliomas

New cancer therapies are being developed that trigger tumour apoptosis and an in vivo method of apoptotic detection and early treatment response would be of great value. Magnetic resonance spectroscopy (MRS) can determine the tumour biochemical profile in vivo, and we have investigated whether a spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Opstad, K S, Bell, B A, Griffiths, J R, Howe, F A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653765/
https://www.ncbi.nlm.nih.gov/pubmed/19223899
http://dx.doi.org/10.1038/sj.bjc.6604933
_version_ 1782165311834816512
author Opstad, K S
Bell, B A
Griffiths, J R
Howe, F A
author_facet Opstad, K S
Bell, B A
Griffiths, J R
Howe, F A
author_sort Opstad, K S
collection PubMed
description New cancer therapies are being developed that trigger tumour apoptosis and an in vivo method of apoptotic detection and early treatment response would be of great value. Magnetic resonance spectroscopy (MRS) can determine the tumour biochemical profile in vivo, and we have investigated whether a specific spectroscopic signature exists for apoptosis in human astrocytomas. High-resolution magic angle spinning (HRMAS) (1)H MRS provided detailed (1)H spectra of brain tumour biopsies for direct correlation with histopathology. Metabolites, mobile lipids and macromolecules were quantified from presaturation HRMAS (1)H spectra acquired from 41 biopsies of grades II (n=8), III (n=3) and IV (n=30) astrocytomas. Subsequently, TUNEL and H&E staining provided quantification of apoptosis, cell density and necrosis. Taurine was found to significantly correlate with apoptotic cell density (TUNEL) in both non-necrotic (R=0.727, P=0.003) and necrotic (R=0.626, P=0.0005) biopsies. However, the ca 2.8 p.p.m. polyunsaturated fatty acid peak, observed in other studies as a marker of apoptosis, correlated only in non-necrotic biopsies (R=0.705, P<0.005). We suggest that the taurine (1)H MRS signal in astrocytomas may be a robust apoptotic biomarker that is independent of tumour necrotic status.
format Text
id pubmed-2653765
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26537652010-03-10 Taurine: a potential marker of apoptosis in gliomas Opstad, K S Bell, B A Griffiths, J R Howe, F A Br J Cancer Molecular Diagnostics New cancer therapies are being developed that trigger tumour apoptosis and an in vivo method of apoptotic detection and early treatment response would be of great value. Magnetic resonance spectroscopy (MRS) can determine the tumour biochemical profile in vivo, and we have investigated whether a specific spectroscopic signature exists for apoptosis in human astrocytomas. High-resolution magic angle spinning (HRMAS) (1)H MRS provided detailed (1)H spectra of brain tumour biopsies for direct correlation with histopathology. Metabolites, mobile lipids and macromolecules were quantified from presaturation HRMAS (1)H spectra acquired from 41 biopsies of grades II (n=8), III (n=3) and IV (n=30) astrocytomas. Subsequently, TUNEL and H&E staining provided quantification of apoptosis, cell density and necrosis. Taurine was found to significantly correlate with apoptotic cell density (TUNEL) in both non-necrotic (R=0.727, P=0.003) and necrotic (R=0.626, P=0.0005) biopsies. However, the ca 2.8 p.p.m. polyunsaturated fatty acid peak, observed in other studies as a marker of apoptosis, correlated only in non-necrotic biopsies (R=0.705, P<0.005). We suggest that the taurine (1)H MRS signal in astrocytomas may be a robust apoptotic biomarker that is independent of tumour necrotic status. Nature Publishing Group 2009-03-10 2009-02-17 /pmc/articles/PMC2653765/ /pubmed/19223899 http://dx.doi.org/10.1038/sj.bjc.6604933 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Opstad, K S
Bell, B A
Griffiths, J R
Howe, F A
Taurine: a potential marker of apoptosis in gliomas
title Taurine: a potential marker of apoptosis in gliomas
title_full Taurine: a potential marker of apoptosis in gliomas
title_fullStr Taurine: a potential marker of apoptosis in gliomas
title_full_unstemmed Taurine: a potential marker of apoptosis in gliomas
title_short Taurine: a potential marker of apoptosis in gliomas
title_sort taurine: a potential marker of apoptosis in gliomas
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653765/
https://www.ncbi.nlm.nih.gov/pubmed/19223899
http://dx.doi.org/10.1038/sj.bjc.6604933
work_keys_str_mv AT opstadks taurineapotentialmarkerofapoptosisingliomas
AT bellba taurineapotentialmarkerofapoptosisingliomas
AT griffithsjr taurineapotentialmarkerofapoptosisingliomas
AT howefa taurineapotentialmarkerofapoptosisingliomas